Hepatitis Diagnostic Test Market: Market Size & Forecast 2026

The hepatitis diagnostic test market comprises a range of diagnostic products and services designed to identify and monitor hepatitis virus infections, which remain a significant global health concern affecting millions worldwide. These tests include serological assays for antibody and antigen detection, nucleic acid amplification tests for viral load quantification, liver function panels, and imaging modalities. The market serves hospitals, diagnostic laboratories, blood banks, and research institutions, with testing essential for diagnosis, treatment monitoring, and epidemiological surveillance.

• •Tests target multiple hepatitis virus types including A, B, C, D, and E, each requiring specific diagnostic approaches
• •Primary test categories include immunoassays, molecular diagnostic tests, and biochemical liver function assessments
• •Market encompasses both point-of-care rapid tests and laboratory-based high-throughput screening platforms

Rising global prevalence of viral hepatitis, particularly chronic hepatitis B and C infections, continues to drive demand for diagnostic testing across both developed and emerging markets. Government initiatives and the World Health Organization's targets to eliminate viral hepatitis as a public health threat by 2030 have expanded screening and awareness programs worldwide. Additionally, increasing healthcare infrastructure investment in developing regions and the growing availability of advanced diagnostic technologies support market expansion.

• •WHO global health sector strategies targeting hepatitis elimination by 2030
• •Increasing incidence of liver disease complications from undiagnosed chronic infections
• •Rising adoption of molecular diagnostic technologies offering higher sensitivity and specificity

The market is segmented by test type, including blood tests (ELISA, rapid tests), liver function tests, molecular tests, and imaging or biopsy procedures, with blood-based serological tests commanding the largest share. By hepatitis type, the market covers testing for hepatitis A, B, C, D, and E, with hepatitis B and C representing the most significant segments due to their chronic nature and global prevalence. Geographically, North America leads the market, followed by Europe and Asia-Pacific, where growing healthcare access and disease burden drive demand.

• •Hepatitis B and C testing dominate the market due to chronic infection prevalence and treatment monitoring requirements
• •North America and Europe hold significant shares due to advanced healthcare infrastructure and established screening protocols
• •Asia-Pacific represents a fast-growing regional market driven by large populations and improving healthcare access

What are the recent trends and outlook?

The market is moving toward integrated diagnostic solutions combining multiple hepatitis markers in single platforms, along with increased adoption of point-of-care testing to expand screening access in resource-limited settings. Emerging technologies including next-generation sequencing and artificial intelligence-powered diagnostic interpretation are expected to enhance test accuracy and predictive capabilities. The market's projected growth reflects sustained demand driven by ongoing elimination initiatives and technological innovation across both developed and developing healthcare systems.

• •Growing preference for multiplex assays capable of detecting multiple hepatitis types simultaneously
• •Rising adoption of decentralized point-of-care testing to improve access in remote and underserved populations
• •Integration of digital health platforms and connected diagnostic devices for enhanced disease surveillance